Clinical Trials on Plasma Volume

Total 4393 results

Oregon Health and Science University

Withdrawn

Stop Hypernatremia, Use Metolazone, for Aggressive, Controlled, Effective Diuresis (SHUM)

Respiratory Failure | Hypernatremia | Volume Overload

United States
Klinik für Kardiologie, Pneumologie und Angiologie

Completed

Role of Oxygen for Vascular Dysfunction

Endothelial Dysfunction | Oxygen Saturation | Microcirculation | FMD | IMT | Oxygen Pressure | Carbon Dioxide Pressure | Forced Expiratory Volume After 1 Second

Germany
University of Exeter
Quorn

Completed

Protein Extrusion and Postprandial Amino Acid Handling (BABE)

Postprandial Plasma Amino Acid Availability

United Kingdom
Astellas Pharma Inc

Completed

A Study to Compare the Oral Absorption of ASP1941 Among Two Types of Tablets

Healthy | Plasma Concentration of ASP1941

Japan
Astellas Pharma Inc

Completed

A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet (Without Water) and Conventional Tablet

Healthy | Plasma Concentration of YM060

Japan
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

Plasma Cell Leukemia

United States
University of Alabama at Birmingham

Completed

Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation

Therapeutic Plasma Exchange | Anticoagulant Therapy

United States
RenJi Hospital

Not yet recruiting

A Comparison of Stroke Volume Variation for Prediction of Fluid Responsiveness

Fluid Responsiveness | Stroke Volume Variation | SVV-FloTrac | Thoracic Electrical Bioimpedance

China
Assiut University

Not yet recruiting

Cervical Volume and Prediction of Preterm Labor

Preterm Labor | Cervical Volume
RenJi Hospital

Not yet recruiting

A Comparison of Thoracic Electrical Bioimpedance and FloTrac/Vigileo

Fluid Responsiveness | Stroke Volume Variation | SVV-FloTrac | Thoracic Electrical Bioimpedance

China
Ludhmila Abrahão Hajjar
University of Sao Paulo

Unknown

Comparison of Dynamic Fluid Responsiveness by EIT and Transpulmonary Thermodilution in Postoperative of CABG Patients

Hemodynamic Monitoring | Fluid Therapy | Coronary Artery Bypass Grafting | Stroke Volume

Brazil
National Cancer Institute (NCI)

Completed

Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Non-Secretory Plasma Cell Myeloma | Plasmacytosis

United States
Astellas Pharma Inc

Completed

Study to Evaluate the Effect of Food Intake on the Plasma Concentration Changes of Quetiapine After Oral Administration of FK949E in Healthy Volunteers

Healthy | Plasma Concentration Change of Quetiapine

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects

Healthy Subjects | Plasma Concentration of Mirabegron

Japan
Sisli Hamidiye Etfal Training and Research Hospital

Completed

Gastric Ultrasound in Diabetic and Non-Diabetic Pregnant Women

Pulmonary Aspiration | Fasting | Gastric Volume | Diabetic Pregnancy | Gastric Ultrasonography

Turkey
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia | Loss of Chromosome 17p | Autologous Hematopoietic Stem Cell Transplant Recipient

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation (PCL-2)

Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

Plasma Cell Leukemia

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

Plasma Cell Leukemia

China
University of Jordan
Nutritional Fundamentals for Health

Completed

Determination of Pharmacokinetics of Different Curcuminoids Preparations: Pilot Study

Plasma Levels of Different Curcuminoids Preparations

Jordan
Fundacion Clinic per a la Recerca Biomédica

Unknown

Albumin for Management of Hypervolemic Hyponatremia (AlbuCAT) (AlbuCAT)

Cirrhosis, Liver | Hyponatremia With Excess Extracellular Fluid Volume

Spain
U.S. Army Medical Research and Development Command

Completed

Ascending Doses of Autologous FDP vs FFP (FDP)

Freeze Dried Plasma in Healthy Volunteers

United States
Research & Diagnostic Antibodies
National Institute of General Medical Sciences (NIGMS)

Completed

Normal Human Plasma Level of iNOS Study

Normal Human Plasma Level of iNOS

United States
Mayo Clinic

Active, not recruiting

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Smoldering Plasma Cell Myeloma

United States
Erebouni Medical Center
Fisher and Paykel Healthcare

Recruiting

ROX Index and ROX Vector to Predict Nasal High Flow / Continuous Positive Airway Pressure Failure in Neonates

Predictive Value of Tests

Armenia
Roswell Park Cancer Institute

Recruiting

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Smoldering Plasma Cell Myeloma

United States
Mayo Clinic

Recruiting

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Not yet recruiting

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Abdullah Khan

Terminated

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
University of California, San Francisco
Janssen Pharmaceuticals; Multiple Myeloma Research Foundation

Terminated

Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
Takeda

Active, not recruiting

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
OHSU Knight Cancer Institute
Sanofi; Oregon Health and Science University

Active, not recruiting

Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Withdrawn

Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
University of Washington
National Cancer Institute (NCI); SecuraBio

Terminated

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI); Novartis Pharmaceuticals

Completed

Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Completed

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Assiut University

Unknown

Cell Free Circulating Nucleic Acids as New Tumor Diagnostics From Human Plasma Samples.

New Tumor Diagnostics From Human Plasma Samples

Egypt
CARsgen Therapeutics Co., Ltd.

Not yet recruiting

Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL

Multiple Myeloma | Primary Plasma Cell Leukemia
Shanghai Changzheng Hospital
CARsgen Therapeutics Co., Ltd.

Recruiting

Study of CT071 Injection in RRMM or PPCL

Multiple Myeloma | Primary Plasma Cell Leukemia

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

Plasma Cell Myeloma | Plasma Cell Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell Myeloma | Plasmacytoma | Plasma Cell Leukemia

United States
Array Biopharma, now a wholly owned subsidiary...

Completed

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma, Plasma Cell Leukemia

United States
Kaiser Permanente
Donaghue Medical Research Foundation

Completed

Evaluating the Impact of a Value-based Prescription Drug Formulary (VBF-e)

Value-Based Health Insurance

United States
South Dakota State University
University of Missouri-Columbia; Ohio State University; Michigan State University and other collaborators

Completed

Voices for Food: Food Policy Councils, Food Security and Healthy Food Choices (VFF)

Food Security | Nutritive Value

Clinical Trials on Plasma Volume

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations